Finnish Heart Research Technology VTT's Method Eases Early Diagnosis of Severe Heart Muscle Disease

Dilated cardiomyopathy, a heart muscle disease leading to dilation and impaired contraction of the left ventricle, is a severe and often familial disease. It is difficult to diagnose the disease with cardiac ultrasound, particularly at an early stage when there are only minimal, early changes of the heart. VTT Technical Research Centre of Finland has developed a method based on cardiac MRI, currently in research use, to help the physician to identify disease-related changes of the heart at an early stage.

In dilated cardiomyopathy, the heart dilates and impaired contraction of the left ventricle leads to heart failure. The disease may be suspected based on symptoms and an enlarged cardiac shadow revealed in a chest x-ray, for example. The diagnosis is typically verified by cardiac ultrasound examination. At an early stage, minimal changes of the heart are difficult to observe with ultrasound because their distinction from normal variation can challenge even an experienced cardiologist.

The method developed during VTT's co-operation project utilises database data on variations in cardiac muscle measured with MRI scans taken from different projections. Cardiac MRIs of the patient are compared with database data on normal variation in healthy hearts, and with disease-related variation in healthy and sick hearts. This corresponds to the knowledge of an experienced physician on the appearance of cardiac MRI images and their deviations. With the help of this method developed by VTT, the essential information for diagnosis is easily available for all physicians regardless of their experience in interpreting cardiac MRIs.

Measurement values have been identified with the help of MRI to enable diagnosis at a very early stage of the disease. The key issue of the method is to develop a new visualisation technique, which enables presentation of essential information from a very large measurement set in an easily interpretable form. In addition, this research has developed a disease index representing the severity of disease, which offers a simple method for monitoring the disease and its treatment, for example.

The developed methods will be first applied, in a research context, to research and analysis of changes produced by various diseases and disease mechanisms. Later the goal is to provide a method for clinical use to assist physicians in diagnosing. The research will be explored further by applying the methods in the research of other heart and brain diseases. In addition to imaging data, the analysis method will include cell metabolism data acquired from blood samples, for example.

Information on dilated cardiomyopathy
Dilated cardiomyopathy is a severe heart disease, which causes dilation of the myocardium and is familial in as many as one third of cases. Because of this, it is recommended that the first-degree family members of the patient, even those with no symptoms, be examined to identify potential evidence of incipient disease. To organise monitoring and treatment, it is vital to identify as reliably as possible all of those, including the symptomless, who will later be at risk of developing the disease. In some cases, those at risk of developing the disease can be identified with DNA analysis.

A diseased myocardium can not be healed but the symptoms can be greatly alleviated with heart failure medication. Incidence of the disease in the adult population is approximately 36.5/100,000 and markedly lower among children. In Finland, dilated cardiomyopathy is the leading cause for heart transplantation and causes a considerable amount of morbidity and premature mortality among the working population.

Partners of the research are VTT Technical Research Centre of Finland, the Hospital District of Helsinki and Uusimaa (HUS), the Kuopio University Hospital (KYS) and the University of Kuopio.

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders. For further information, please visit http://www.vtt.fi.

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

AI in Healthcare: How do We Get from Hyp…

The Highland Marketing advisory board met to consider the government's enthusiasm for AI. To date, healthcare has mostly experimented with decision support tools, and their impact on the NHS and...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...